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Mesenchymal stromal cell-like (MSCl) cells generated from human embryonic
stem cells are considered to be an eligible cell line to model the immunomodula-
tory behavior of mesenchymal stromal cells (MSCs) in vitro. Dendritic cells (DCs)
are essential players in the maintenance and restoration of the sensitive balance
between tolerance and immunity. Here, the effects of MSCl cells on the in vitro
differentiation of human monocytes into DCs were investigated. MSCl cells pro-
mote the differentiation of CTLA-4 expressing DCs via the production of all-trans
retinoic acid (ATRA) functioning as a ligand of RARa, a key nuclear receptor in DC
development. These semi-matured DCs exhibit an ability to activate allogeneic,
naive T cells and polarize them into IL-10 + IL-17 + double-positive T helper cells
in a CTLA-4-dependent manner. Mapping the molecular mechanisms of MSC-
mediated indirect modulation of DC differentiation may help to expand MSCs’
clinical application in cell-free therapies.
INTRODUCTION
Due to their multipotent differentiation ability and strong immunomodulatory potential, mesenchymal
stromal cells (MSCs) are promising candidates for cell-based therapy of several inflammatory, immune-
mediated, and degenerative diseases (Saeedi et al., 2019). There are a number of ongoing clinical trials
related to the immunomodulatory effects of MSCs or linked to graft enhancement utilizing their immuno-
suppressive functions (Wang et al., 2018). However, the exact cellular and molecular mechanisms underly-
ing the MSC-mediated immunomodulation have yet to be revealed. Despite a large number of studies
focusing on changes in cells and tissues followingMSCs administration, several pieces of the puzzle are still
missing and results are often inconsistent. Possible reasons include that MSCs from different sources and
under different culture conditions may have diverse phenotype and epigenetic background, secrete
distinct patterns of soluble factors and possess different capacities to proliferate (Weiss and Dahlke,
2019). One of the strategies to overcome these limitations is the use of MSC-like (MSCl) cell lines derived
from human pluripotent stem cells, generating unlimited numbers of early passage MSCs with consistent
quality and immune suppressive properties (Kimbrel et al., 2014).
We have earlier demonstrated in a collaborative study that based on their phenotypic and functional prop-
erties such as differentiation potential and immunomodulatory activity, human MSCl cells generated from
pluripotent HUES9 embryonic stem cells are eligible to model the behavior of bone marrow-derived MSCs
in vitro (Varga et al., 2011). In a recent study, we have provided a body of evidence that these MSCl cells are
able to modulate the responses of monocyte-derived dendritic cells (moDCs) to retinoic acid-inducible
gene I receptor-mediated activation (Bacskai et al., 2015). Human moDCs stimulated in the presence of
MSCl cells exhibited reduced expression of phenotypic indicators of DC activation, lower production of
TNF-a, CXCL10, IL-12 and IFNg, as well as a decreased migration and T cell polarization as compared
to moDCs activated in the absence of MSCl cells (Bacskai et al., 2015). These prior observations indicate
that activation of mature moDCs can be efficiently suppressed by MSCl cell-derived signals and mecha-
nisms. In this study, we investigated whether and how the in vitro differentiation of human monocytes
into DCs is altered by MSCl cells.iScience 24, 102312, April 23, 2021 ª 2021 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. The cytokine and chemokine production of moDCs is modulated by MSCl cells
To examine the regulatory effects of MSCl cells or the MSCl-CM on the cytokine and chemokine production of moDCs, on
day 4 of moDC differentiation the integrated density of soluble mediators was measured by Human XL Cytokine Array Kit
(A) and the concentration of secreted cytokine IL-6, IL-10, TGFb was detected by ELISA (B).
In case of co-cultures, the diagrams represent the secretion of cytokines released by moDCs and MSCl cells. Mean values
of relative cytokine levels and concentrations were calculated from 4 or more independent experiments. Data are
represented as individual data points with the mean G standard deviation. In the statistical analysis, one-way ANOVA
followed by Bonferroni’s multiple comparison test was used with significance defined as *p < 0.05, **p < 0.01 and
****p < 0.0001.





The cytokine and chemokine production of moDCs is modulated by MSCl cells
To analyze the direct and indirect immunomodulatory effects of MSCl cells, moDCs were differentiated in
the presence of MSCl-CMorMSCl cells and relative cytokine, chemokine and other soluble protein levels in
the cell culture supernatants were investigated using a protein array (Figure S1). It was observed that sol-
uble factors released by MSCl cells remarkably altered the protein secretion profile of moDCs. Elevated
levels of BAFF, complement factor D, EGF, IL-2, IL-22, lipocalin-2, TGFa, TIM3, myeloperoxidase, C-reac-
tive protein, and Dkk-1, while decreased productions of ICAM-1 and EMMPRIN were detected in the su-
pernatant of moDCs differentiated in the presence of MSCl-CM (Figure 1A). However, increased levels
of Vitamin D BP, Endoglin, ENA78, GDF-15, GRO-a, IL-24, MCP-3, VEGF, IL-8, IL-10, and IFNg, but reduced
amounts of FGF-19, Osteopontin, CD31, and IL-18 Bpa were found in the supernatant of moDC-MSCl cell2 iScience 24, 102312, April 23, 2021
Figure 2. MSCl cells and MSCl-CM modify the cell surface expression of CD14, DC-SIGN/CD209 and group1 CD1
family members
CD14+ monocytes were cultured with recombinant IL-4 and GM-CSF GMSCl cells or MSCl-CM for 4 days. On day 4, the
cell surface expression of CD14 and DC-SIGN (A), and that of CD1a, CD1b, and CD1c (B) were analyzed by flow cytometry
on monocyte-derived cells.
To exclude the possibility of unspecific staining because of the presence of dead cells, the viability of cells was measured
by 7-aminoactinomycin D (7-AAD) staining using flow cytometry (C). The MFI (median fluorescence intensity) and the
mean values of the ratio of cells positive for the measured surface molecules were calculated from at least three
independent experiments. Data are represented as individual data points with the mean G standard deviation.
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Histograms show one of at least four independent experiments. In the statistical analysis, one-way ANOVA followed
by Bonferroni’s multiple comparison test was used with significance defined as *p < 0.05, **p < 0.01, ***p < 0.001 and
****p < 0.0001.




Articleco-cultures (Figure 1A). Both exposure to MSCl-CM and direct moDC-MSCl cell contact raised the secre-
tion of IL-19, VCAM-1, leptin, IL-6, CD14, FGF basic, IGFBP2, TFF3 and TfR, while the production of IL-27,
Cystatin C, chitinase 3-like 1, MMP-9, and PDGF-AB/BB was diminished in the presence of either MSCl-CM
or MSCl cells (Figure 1A). To validate the protein array results, concentrations of some inflammatory (IL-6)
and anti-inflammatory (IL-10 and TGFb) mediators were determined by ELISA (Figure 1B). In the superna-
tant of moDC-MSCl cell co-cultures significantly enhanced IL-6 and IL-10 productions were detected, while
in the presence of MSCl-CMmoDCs secreted significantly more IL-6, IL-10 and TGFb than control cells (Fig-
ure 1B). These results demonstrate that the baseline levels of both inflammatory and anti-inflammatory me-
diators in moDCs cultures can be modulated by MSCl cells through the action of soluble or membrane-
bound molecules.MSCl cells modify the phenotype of monocyte-derived cells
To get insight into how the presence of MSCl-CM or MSCl cells affects the phenotypic characteristics of
moDC differentiated in vitro, we monitored the expression of cell surface molecules by flow cytometry.
During the differentiation of moDCs in the presence of GM-CSF and IL-4, the expression of CD14 is
downregulated (Sallusto and Lanzavecchia, 1994), while that of DC-SIGN (Geijtenbeek et al., 2000) and
group 1 CD1 family members (Sallusto and Lanzavecchia, 1994) is upregulated. In our experiments, the
percentage of CD14+ cells was higher in the presence of MSCl-CM or MSCl cells than in control cell cul-
tures (Figure 2A). While the ratio of DC-SIGN+ cells was similar in treated and control cell cultures, the cell
surface expression of DC-SIGN molecule was significantly downregulated on MSCl-exposed cells (Fig-
ure 2A). We found that under our experimental conditions, approx. 40% of untreated cells expressed
group 1 CD1 family members including CD1a, CD1b, and CD1c (Figure 2B). Exposure to either MSCl-
CM or MSCl cells significantly reduced the cell surface expression of these glycolipid receptors on mono-
cyte-derived cells, while these treatments did not modify their viability (Figure 2C). This observation sug-
gests that the presentation of lipid and glycolipid antigens by monocyte-derived cells through group 1
CD1 proteins may be negatively modulated by MSCl cells either in a direct or an indirect manner. For
further characterization of phenotypic changes of MSCl-CM- and MSCl cell-treated monocyte-derived
cells, expression of CD163, a macrophage scavenger receptor (Skytthe et al., 2020), was investigated.
Interestingly, treatment with MSCl-CM induced only a slight increase in the frequency of CD163+ cells,
whereas exposure to MSCl cells triggered a significant rise in the ratio of the macrophage marker-ex-
pressing cells (Figure S2A).
We also found that MSCl-CM significantly increased the cell surface levels of the peptide antigen-present-
ing HLA-DQ and the co-stimulatory molecule CD86, whereas contact with MSCl cells significantly
enhanced the expression of both CD80 and CD86 on monocyte-derived cells (Figure 3A). Augmented
expression of PD-L1, a co-inhibitory molecule, could also be detected on monocyte-derived cells in the
presence of MSCl cells (Figure 3B). Importantly, an increased expression of another co-inhibitory molecule
CTLA-4 on monocyte-derived cells was induced exclusively by MSCl-CM (Figure 3B). Elevated expression
of CTLA-4 was induced byMSCl-CM in a time-dependent manner and a statistically significant difference in
CTLA-4 levels on treated and control cells was found on day 4 of treatment (Figure 3C, left panel). A four-
fold increase in the expression of CTLA-4 at mRNA level was also detected in four-day-old monocyte-
derived cells differentiated in the presence of MSCl-CM compared to control moDCs (Figure 3C, right
panel). When four-day-old immature moDCs were co-cultured with MSCl cells for 48 hr a remarkable in-
crease in the expression of CD80, CD86, and PD-L1 on moDCs was observed (Figure S3). However,
when immature moDCs were treated with MSCl-CM for a same period of time no or minor changes in
the levels of co-stimulatory and co-inhibitory molecules on moDCs could be detected, suggesting that
MSCl-derived soluble factors are able to modify the immune regulatory phenotype of moDCs only at
the early stage of their development (Figure S3). These observations together with microscopic
morphology of the cells (Figure S2B) indicate that MSCl-CM has a potential to regulate the differentiation
of monocytes toward CD1aDC-SIGN+CD163low semi-matured moDCs, whereas MSCl cells promote the
differentiation of CD1aDC-SIGNlowCD163high M2 macrophage-like cells.4 iScience 24, 102312, April 23, 2021
Figure 3. MSCl cells and MSCl-CM alter the cell surface expression of molecules involved in T cell activation
CD14+ monocytes were cultured with recombinant IL-4 and GM-CSF GMSCl cells or MSCl-CM for 4 days. On day 4, monocyte-derived cells were analyzed
for the cell surface expression of the T cell stimulatory CD80, CD86, HLA-DQ (A) and the regulatory CTLA-4 and PD-L1 (B) molecules by flow cytometry. The
frequency of CTLA-4-expressing cells was monitored on each day during the differentiation process (C).
The gene expression level of CTLA-4 was measured by qPCR on day 4 (C). The MFI and the mean values of the ratio of cells positive for the measured cell
surface molecules were calculated from at least four independent experiments. Mean values of relative mRNA levels were calculated from three
independent experiments. Data are represented as individual data points with the mean G standard deviation. Histograms show one of at least four
independent experiments. In the statistical analysis, one-way ANOVA followed by Bonferroni’s multiple comparison test (A and B), as well as Student’s t-test
and Mann-Whitney rank-sum test (C) were used with significance defined as *p < 0.05, **p < 0.01.




ArticleMSCl cells change the phenotypic characteristics of moDCs at least partially via ATRA
production
It has recently been reported that RARa is able to regulate the differentiation of specialized DCs from human
blood monocytes (Hashimoto-Hill et al., 2018). Therefore, to investigate the molecular mechanisms guiding
the phenotypic changes of moDCs in the presence of MSCl-CM, we analyzed the role of RARa in this process




ArticleThe expression level of CD1a on moDCs was significantly lowered by soluble factors in MSCl-CM (Figures
2C and 4A) and when cells were treated with ATRA (Figure 4A). As expected, BMS614 prevented the effect
of ATRA on CD1a expression. The addition of BMS614 to MSCl-CM induced some but statistically insignif-
icant increase in the expression of CD1a (Figure 4A). Inhibition of RARa blocked the effect of ATRA on
HLA-DQ expression and also decreased the ability of MSCl-CM to intensify peptide antigen presentation;
however, the observed differences were statistically non-significant (Figure 4A). The enhancement in the
expression of T cell co-stimulatory and co-inhibitory molecules on moDCs by ATRA or also by MSCl-CM
was largely dependent on functional RARa receptor (Figure 4A). Indeed, the upregulation of CD86 expres-
sion on moDCs by ATRA or MSCl-CM was significantly reduced when the function of RARa was inhibited.
Furthermore, enhanced ratio of CTLA-4+ moDCs induced by ATRA or MSCl-CM was also significantly
diminished by the selective blockade of RARa (Figure 4A).
Next, it was further analyzed whether MSCl cells modify the immune regulatory potential of moDCs via
ATRA production. First, expression of genes known to play a role in ATRA synthesis was investigated in
MSCl cells and found that these cells express retinol dehydrogenase 10 (RDH10), and aldehyde dehydro-
genase 1 family members ALDH1A1 and ALDH1A3, but not ALDH1A2 (Figure 4B). In next series of exper-
iments, the activity of aldehyde dehydrogenase isoenzymes was inhibited using a highly selective inhibitor
DEAB (Morgan et al., 2015) in MSCl cells and the differentiation of moDCs in the presence of ATRA
deficient MSCl-CM was monitored. MSCl-CM collected from cultures of MSCl cells with inhibited ATRA
synthesis was still able to significantly enhance the cell surface expression of HLA-DQmolecule on moDCs
(Figure 4C). In contrast to HLA-DQ, changes in the expression of CD1a, CD86 and CTLA-4 on moDCs
exposed to MSCl-CM was dependent on ATRA production by MSCl cell (Figure 4C).
Taken together, these results suggest that MSCl cells bring about the phenotypic changes of moDCs at
least partially via ATRA production.
CTLA-4 expression on moDCs differentiated in the presence of MSCl-CM is essential to drive
the development of IL-17- and IL-10-producing T cells
To further dissect the immune regulatory capacity of moDCs exposed to MSCl-CM, ELISPOT assays appro-
priate to monitor the moDC-mediated allogeneic T-lymphocyte activation were used. It was found that
moDCs treated with MSCl-CM have a potential to significantly increase the polarization of T cells produc-
ing IL-17 (Figure 5A) and IL-10 (Figure 5B). Moreover, flow cytometric analysis revealed that moDCs
cultured in the presence of MSCl-CM triggered the polarization of IL-10+IL-17+ double-positive T helper
cells (Figure 5C).
To analyze the role of CTLA-4 in moDC-mediated T cell polarization, the CTLA-4-mediated signaling
pathway was inhibited using specific antibodies. Unexpectedly, a blockade of CTLA-4 signaling in MSCl-
CM-treated moDCs significantly reduced their ability to trigger the development of IL-17- and IL-10-pro-
ducing T cells (Figures 5A–5C). Importantly, isotype control antibodies did not affect the IL-10 and IL-17
production of T cells primed by MSCl-CM-treated moDCs (Figure S4). In parallel experiments, a CTLA-4
blockade did not modify significantly the Th1- and Th2-polarizing capacity of MSCl-CM-exposed moDCs
(Figure S5). When moDCs were treated with MSCl-CM in the presence of the specific RARa antagonist
(BMS614), which partially prevented the induction of CTLA-4 expression on moDCs by MSCl-CM (Fig-
ure 4A), they also displayed a reduced capability to bring about the polarization of IL-17- and IL-10-produc-
ing T cells (Figure S6). Although the observed decreases in the number of polarized T cells in the presence
of the RARa inhibitor were not statistically significant (Figure S6).
These results clearly demonstrate that the T cell-polarizing capacity of moDCs can be modulated by solu-
ble factors derived from the MSCl cells. Furthermore, the ability of MSCl-CM-treated moDCs to induce po-
larization of IL-17- and IL-10-producing T cells is dependent on the level of functional CTLA-4 molecules on
their surface.
DISCUSSION
Human DCs represent a very heterogeneous cell population, including distinct subsets associated with
both inflammatory and regulatory functions, and with remarkable phenotypic and functional plasticity
(Qian and Cao, 2018). The interplays between DCs and other cell types depend on the developmental sta-
tus and the functional activities of DCs determined by current humoral and cellular components of the6 iScience 24, 102312, April 23, 2021
Figure 4. MSCl cells change the immune regulatory potential of moDCs at least partially via nuclear factor RARa
and ATRA
To investigate how MSCl-CM affects the differentiation of moDC, monocytes were differentiated in the presence or
absence of 1 nM RARa activator, ATRA followed by a 75min incubation period with or without 1 mMBMS614 (BMS) specific
RARa-antagonist prior to exchange the cell culture medium to RPMI-1640 or MSCl-CM. Monocytes were differentiated
into moDC in the presence or absence of MSCl-CM for 4 days. On day 4, moDCs were analyzed for the cell surface
expression of CD1a, the T cell stimulatory HLA-DQ, CD86 and the T cell co-inhibitory CTLA-4 proteins by flow cytometry
(A).
To test and compare the capability of freshly isolated monocytes, moDCs and MSCl to produce ATRA, mRNA was
extracted from the different cell types. The relative mRNA expression level of target genes RDH10, ALDH1A1, ALDH1A2,
and ALDH1A3 was measured by qRT-PCR (B).
To prove the effect of ATRA to the differentiation process of monocytes into moDCs, the RALDH enzymes essential for
the synthesis of ATRA were inhibited specifically by 1mM DEAB in the MSCl cultures for 24 hr before the collection of
MSCl-CM. CD14+ monocytes were cultured with recombinant IL-4 and GM-CSF and MSCl-CM with or without ATRA for
4 days. On day 4, moDCs were analyzed for the cell surface expression level of CD1a, HLA-DQ, CD86 and the regulatory
CTLA-4 molecules by flow cytometry (C).
Mean values of MFI and moDCs positive for the measured cell surface antigen were calculated from at least four
independent experiments. Mean values of relative mRNA levels were calculated from three independent experiments.
Data are represented as individual data points with the mean G standard deviation. In the statistical analysis, one-way
ANOVA followed by Bonferroni’s multiple comparison test was used with significance defined as *p < 0.05, **p < 0.01 and
***p < 0.001, ****p < 0.0001.
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Figure 5. CTLA-4 expression on moDCs differentiated in the presence of MSCl-CM is essential to drive the
development of IL-10- and IL-17-producing T cells
CD14+ monocytes were differentiated into moDC in the presence or absence of MSCl-CM for 4 days. On day 4, the
moDCs were treated with anti-CTLA-4 blocking antibody and were co-cultured with allogeneic T lymphocytes for further
3, 5 or 9 days. ELISPOT assays were used to determine the number of IL-17- (A) and IL-10- (B) producing T cells. The
average values of spot numbers indicating T-lymphocyte responses were counted from 3micro-wells. Mean values of spot
numbers were calculated from 3 independent experiments. IL-10- and IL-17-producing CD4+ T cells were detected by
flow cytometry (C).
Mean values of the ratio of T cells positive for the measured cell intracellular cytokines were calculated from four
independent experiments. Data are represented as individual data points with the mean G standard deviation. Contour
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plots show one of the three independent experiments. In the statistical analysis, one-way ANOVA followed by
Bonferroni’s multiple comparison test was used with significance defined as *p < 0.05.




Articlegiven tissue milieu (Dong et al., 2015). MSCs have the potential to modulate the differentiation and the
functions of T and B lymphocytes as well as innate immune cells including granulocytes (Park et al.,
2012), natural killer (NK) cells (Abumaree et al., 2018), monocytes (Chen et al., 2014), macrophages (Vasan-
dan et al., 2016), and DCs (Jiang et al., 2005). However, the capacity of MSCl cells and MSCl-CM to alter the
initial differentiation of human DCs from monocytes has not yet been investigated.
During both homeostasis and inflammation, circulating monocytes leave the blood circulation and migrate
into tissues where they are able to differentiate into DCs (Shi and Pamer, 2011). Several previous studies
have examined the effects of MSCs on the differentiation of human moDCs. When irradiated (30 Gy) bone
marrow-derived MSCs were co-cultured with freshly isolated monocytes (1:5) together with GM-CSF and
IL-4, MSCs greatly inhibitedmonocyte differentiation into immature DCs (Zhang et al., 2004). Most of cultured
cells in the presence of MSCs were negative for CD1a, indicating that the cells had not differentiated into
immature DCs; however, MSCs did not affect the expression of CD14. Co-culture withMSCs substantially pre-
vented the upregulation of the co-stimulatory molecules CD40, CD86, and CD80, as well as down-regulated
HLA-DR expression. On the contrary, MSCs’ supernatants had no effects on DC differentiation (Zhang et al.,
2004). In another study, the transwell chamber systemwas used to separatemonocytes from irradiated (15 Gy)
bone marrow-derived MSCs during differentiation (Jiang et al., 2005). The MSC/monocyte ratio of 1:10 could
completely prevent monocyte differentiation to DCs. Monocytes in the presence of MSC-released factors re-
tained CD14-positive cells without acquisition of CD1a and displayed no up-regulation of CD83 and CD80
(Jiang et al., 2005). In a latter study, in the presence of GM-CSF, IL-4 and non-irradiated bonemarrow-derived
MSCs, monocytes also did not acquire the surface phenotype typical of immature (CD14-, CD1a+) DCs (Spag-
giari et al., 2009). In a recent publication, it has been reported that after co-culture with MSCs from human
induced pluripotent stem cells, monocytes displayed a low expression of CD1a, but a high expression of
CD14, while exhibiting low expression of CD40, CD80, CD83, and HLA-DR (Gao et al., 2017).
In agreement with these previous findings both MSCl cells and MSCl-CM have the potential to regulate the
differentiation of monocytes toward CD14+CD1a cells. In our experimental setupMSCl-CM had only a mi-
nor effect on DC-SIGN levels, whereas exposure to MSCl cells significantly reduced its expression. Further-
more, MSCl cells, but not MSCl-CM, triggered a significant increase in the frequency of cells expressing
CD163, an M2 macrophage marker (Hu et al., 2017). These findings indicate that MSCl-CM regulates the
differentiation of monocytes toward a DC-like phenotype, while MSCl cells switch monocyte differentiation
to M2 macrophage rather than DC direction. In line with our observations, it was reported in a prior study
that bonemarrow-derivedMSCs drive the differentiation of monocytes tomacrophages (Jiang et al., 2005).
We have found that MSCl cells produce several inflammatory and anti-inflammatory factors, among them
IL-6 and IL-10. It comes as no surprise because several soluble factors have been reported to contribute to
the immunomodulatory effects of MSCs, and the roles of IL-6 and IL-10 along with PGE2 and TSG-6 have
been especially well established (Weiss and Dahlke, 2019). It is important to mention that anti-inflammatory
mediators such as IL-6 and IL-10 induce the expression of CD163 (Etzerodt and Moestrup, 2013); therefore,
these cytokines may have a pivotal role in the induction of the differentiation of M2macrophage-like cells in
our experiments. On the other hand, cytokine-independent pathways may also be involved in the MSC-
induced polarization of monocytes/macrophages. In a mouse model of asthma, the phagocytosis of
MSCs caused lung macrophages to turn into a type 2 immunosuppressive phenotype (Braza et al.,
2016). In a recent study, it has been found that the phagocytosis of MSCs caused CD14++CD16 classical
monocytes to polarize toward a CD14++CD16+CD206+ immune regulatory intermediate subtype with anti-
inflammatory properties, increased expression of PD-L1 and production of IL-10 (De Witte et al., 2018).
After phagocytosis of MSCs, these primed monocytes were able to induce CD4+CD25hi Treg formation
in vitro to a significantly higher extent than un-primed monocytes (De Witte et al., 2018). Furthermore,
different Notch ligands could modulate monocyte/macrophage function and determine the M1 versus
M2macrophage polarization (Wang et al., 2010). Since Notch-mediated signals play a role in the protection
against inflammation by MSCs (Li et al., 2008; Zhang et al., 2009; Lu et al., 2020), it is possible that the Notch
pathway becomes activated during the direct contact between MSCl cells and monocytes. Further studies
might reveal the exact mechanisms contributing to the different effects of MSCl cells and MSCl-CM on the




ArticleSemi-mature moDCs differentiated in the presence of MSCl-CM express a low level of group 1 CD1 pro-
teins responsible for the presentation of lipid and glycolipid antigens, while expressing increased levels
of class II MHC molecules and co-stimulatory B7 family members that are essential for the activation of
naive CD4+ T cells. Elevated expression of CTLA-4 on semi-mature moDCs was also induced by MSCl-
CM. This co-inhibitory molecule can be expressed or produced by cells with either myeloid or lymphoid
origin and competes with CD28 on T lymphocytes for binding to co-stimulatory B7 family members (Halpert
et al., 2016; Wang et al., 2002). CTLA-4-expressing DCs were detected in patients suffering from certain
carcinomas, highlighting the importance of this molecule during tumor progression (Han et al., 2014).
Furthermore, genetically modified DCs expressing CTLA-4-Ig fusion protein prevented alloimmune activity
in inflammatory conditions and ensured the survival of allografts through the induction of IL-10 production
by Th17 cells, indicating a tolerogenic role of CTLA-4-expressing DCs in chronic inflammation (Watanabe
et al., 2016). In addition to DCs, monocytes are also able to express CTLA-4, which can be downmodulated
during the differentiation process into moDCs (Laurent et al., 2010). However, our results demonstrate that
the ratio of CTLA-4-expressing cells was very low in the freshly isolated monocyte population and it was
enhanced from the first day of moDC differentiation and further increased in the presence of MSCl cell-
derived factors on day 4. There are no available data in the literature about CTLA-4 expression on M2 mac-
rophages that further confirms the observed distinct effects of MSCl cells and MSC-CM on the differenti-
ation of monocyte-derived cells.
According to our observations, MSCl-CM changed the expression levels of CD1a, CD86, and CTLA-4 on
semi-mature moDCs at least partially via ATRA production. We have demonstrated that MSCl cells express
genes essential for ATRA synthesis. The treatment of moDCs with ATRA mimicked the effects of MSCl-CM
on the expression of CD1a, CD86, and CTLA-4 molecules. ATRA is derived from retinol and acts as a ligand
of nuclear hormone receptors to drive the differentiation program of moDCs (Henning et al., 2015; Nagy
et al., 2012; Bene et al., 2017). The lipid-ligation of nuclear hormone receptors such as PPARg and RARa
results in altered transcriptional regulation of moDC development, metabolism, and T cell polarizing ca-
pacity (Szatmari et al., 2004). Indeed, the ability of MSCl-CM to trigger phenotypic alterations was signif-
icantly diminished by either selective blockade of RARa in moDCs or by that of ATRA synthesis in MSCl
cells. The fact that in the lamina propria of gut, DC subpopulations and MSCs constitutively express the
enzymatic machinery of ATRA production even in the absence of dietary vitamin A (Vicente-Suarez et al.,
2015) further supports our in vitro observations.
We have found that moDCs treated with MSCl-CM have the potential to trigger the polarization of IL-
10+IL-17+ double-positive T helper cells in a CTLA-4-dependent manner. Blocking of CTLA-4 signaling
by specific antibodies significantly reduced the ability of MSCl-CM-treated moDCs to trigger the develop-
ment of IL-17- and IL-10-producing T cells, whereas inhibition of CTLA-4 expression in MSCl-CM-primed
moDCs by applying BMS614, the RARa antagonist, induced only a slight, statistically insignificant decrease
in the number of polarized T cells. This phenomenon can be explained by the fact that BMS614 only
partially prevented the induction of CTLA-4 expression on moDCs by MSCl-CM (Figure 4A).
An increased secretion of IL-6 and TGFb by moDCs differentiated in the presence of MSCl-CM was de-
tected, and these cytokines are known to be crucial regulators of IL-10 production by Th17 cells (Mcgeachy
et al., 2007). We presume that CTLA-4 expressed by semi-matured DCs decreases the levels of available co-
stimulatory molecules for CD28 receptors on the surface of interacting T cells. Our hypothesis is supported
by a recent study showing that myeloid DCs constitutively secrete CTLA-4 in microvesicular structures (Hal-
pert et al., 2016). CTLA-4+ microvesicles can competitively bind B7 co-stimulatory molecules on bystander
DC, resulting in the downregulation of B7 surface expression with significant functional consequences for
T cell responses (Halpert et al., 2016). On the other hand, CTLA-4-mediated signals can also modulate cyto-
kine secretion, as CTLA-4 triggering on mDCs increases IL-10 and reduces IL-8 and IL-12p70 production
(Laurent et al., 2010). IL-17/IL-10 double-producing Th cells are indicative of a nonpathogenic Th17 cell
population that has been shown to have a critical role in restraining Th17 cell-mediated inflammatory
and autoimmune diseases (Mcgeachy et al., 2007; Gagliani et al., 2015). Furthermore, a significantly higher
frequency of IL-17/IL-10 double-producing Th cells was found in acute myeloid leukemia patients than in
healthy controls (Musuraca et al., 2015). The substantial imbalance between IL-17-/IL-10-producing cells
and IL-17/IFN-g-producing cells, together with a reduced frequency in Th1 and Th2 cells, may act as an
immunosuppressive factor in these patients, altering the physiological role of Th17, contributing to the in-




ArticleIn summary, in this work we identified a previously undescribed mechanism for the immunomodulatory ef-
fects of MSCl cells on human DCs. In particular, we showed that monocyte-derived cells differentiated in
the presence of MSCl cells or MSCl-CM could be characterized by a unique phenotype and functional pro-
file. We demonstrated that despite the increased levels of class II MHC and co-stimulatory molecules on
MSCl-CM-treated moDCs, these cells have the ability to induce immunosuppression via promoting the
development of IL-17/IL-10 double-producing Th cells in a CTLA-4-dependent manner.
Limitations of the study
Human MSCs with different origins and under diverse culture conditions may exhibit different capacities to
proliferate and may have diverse phenotypic and functional properties. To overcome these limitations, hu-
man MSC-like cells generated from pluripotent HUES9 embryonic stem cells were used in this study. These
cells proved to be eligible to model the behavior of bonemarrow-derived MSCs in vitro (Varga et al., 2011).
In our experimental conditions, MSCl cells promote the differentiation of CTLA-4 expressing DCs by
production of ATRA, functioning as a ligand of nuclear receptor RARa. These semi-matured DCs activate
allogeneic, naive T cells and polarize them into IL-10- and IL-17-producing T helper cells in a CTLA-4-
dependent manner. Further work is required to confirm these findings in primary human MSCs from
different sources and also to reveal the in vivo relevance of this regulatory mechanism.
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the Lead Contact, Attila Bácsi (etele@med.unideb.hu).
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Supplemental Figures and Legends 
 
 
SFigure 1. The cytokine and chemokine production of moDCs is modulated by MSCl cells 
(Related to Figure 1A). To examine the regulatory effects of MSCl cells or the MSCl-CM on 
protein production of moDCs, on day 4 of moDC differentiation the integrated density of 






SFigure 2. Cell surface expression of CD163 molecule and morphology of monocyte-derived 
cells differentiated in the presence of MSCl cells or MSCl-CM (Related to Figure 2 and Figure 
3). CD14+ monocytes were cultured with recombinant IL-4 and GM-CSF ± MSCl cells or MSCl-
CM for 4 days. On day 4, the cell surface expression of CD163, a macrophage scavenger 
receptor, was analyzed by flow cytometry (A) and the morphology of monocyte-derived cells 
was investigated using an OLYMPUS IX-81 microscope. Images were taken at 10x 
magnification (scale bars, 100 µm) (B). The mean values of the ratio of cells positive for the 
measured cell surface molecules were calculated from three independent experiments. Data 
are represented as mean ± standard deviation. Histograms show one of three independent 
experiments. In the statistical analysis, one-way ANOVA followed by Bonferroni’s multiple 




SFigure 3. The effects of MSCl-CM on the phenotype of immature moDCs (Related to Figure 
3). Freshly isolated CD14+ monocytes were differentiated in the presence of recombinant IL-4 
and GM-CSF for 4 days. On day 4, differentiated moDCs were treated with MSCl-CM or were 
co-cultured with MSCl cells. After 48 hours moDCs were washed from MSCl-CM or separated 
from MSCl cells by using DC-SIGN specific antibodies conjugated with paramagnetic beads. 






SFigure 4. Effect of isotype control antibody on the T cell polarizing capacity of moDCs 
differentiated in the presence of MSCl-CM (Related to Figure 5). CD14+ monocytes were 
cultured with recombinant IL-4, GM-CSF and MSCl-CM for 4 days. On day 4, the moDCs were 
incubated with IgG1 isotype control antibodies and co-cultured with T cells for nine days at a 
moDC : T-cell ratio of 1 : 10. ELISPOT assays were used to determine the number of IL-17 and 
IL-10 producing T cells. The average values of spot numbers indicating T-lymphocyte responses 
were counted from 3 micro-wells. Mean values of spot numbers were calculated from 3 
independent experiments. Data are represented as mean ± standard deviation. In the 
statistical analysis, one-way ANOVA followed by Bonferroni’s multiple comparison test was 





SFigure 5. Th1- and Th2-polarizing capacity of moDCs differentiated in the presence of MSCl-
CM (Related to Figure 5). CD14+ monocytes were cultured with recombinant IL-4, GM-CSF and 
MSCl-CM for 4 days. On day 4, the moDCs were co-cultured with allogeneic T-lymphocytes for 
further 3 or 5 days. ELISPOT assays were used to determine the number of IFNγ (Th1) and IL-
4 (Th2) producing T cells. The average values of spot numbers indicating T-lymphocyte 
responses were counted from 3 micro-wells. Mean values of spot numbers were calculated 
from 3 independent experiments. Data are represented as mean ± standard deviation. In the 





SFigure 6. Effect of RARα inhibition on moDCs differentiated in the presence of MSCl-CM to 
drive the development of IL-10 and IL-17 producing T cells (Related to Figure 4A and Figure 
5). To determine the role of nuclear receptors, moDCs were differentiated in the presence or 
absence of 1 nM RARα activator, ATRA followed by a 75-min incubation period with or without 
1 µM BMS614 (BMS) specific RARα antagonist for 75 min at 37°C atmosphere containing 5% 
CO2 prior to exchange the cell culture medium with or without MSCl-derived conditioned 
medium (MSCl-CM). CD14+ monocytes were cultured with recombinant IL-4, GM-CSF and 
MSCl-CM for 4 days. On day 4, the moDCs were co-cultured with allogeneic T-lymphocytes for 
further five or 9 days. ELISPOT assays were used to measure the number of IL-17- and IL-10-
producing T cells. The average values of spot numbers indicating T-lymphocyte responses 
were counted from 2 micro-wells. Mean values of spot numbers were calculated from 3 
independent experiments. Data are represented as mean ± standard deviation. In the 
statistical analysis, one-way ANOVA followed by Bonferroni’s multiple comparison test was 







Human moDC cultures 
Heparinized leukocyte-enriched buffy coats were obtained from healthy blood donors drawn 
at the Regional Blood Center of the Hungarian National Blood Transfusion Service (Debrecen, 
Hungary) in accordance with the written approval of the Director of the National Blood 
Transfusion Service and the Regional and Institutional Research Ethical Committee of the 
University of Debrecen, Faculty of Medicine (Debrecen, Hungary). Written, informed consent 
was obtained from the blood donors prior blood donation, their data were processed and 
stored according to the directives of the European Union.  
Peripheral blood mononuclear cells (PBMCs) were separated from buffy coats by Ficoll-
Paque Plus (Amersham Biosciences) gradient centrifugation. Monocytes were purified from 
PBMCs by positive selection using immunomagnetic cell separation and anti-CD14-conjugated 
microbeads (Miltenyi Biotec), according to the manufacturer’s instruction. After separation 
on a VarioMACS magnet, 96–99% of the cells were shown to be CD14+ monocytes, as 
measured by flow cytometry. Isolated monocytes were plated at 1.5x106 cell/ml 
concentration in RPMI (Sigma-Aldrich) supplemented by 10% FCS (Gibco) and 1% 
antibiotic/antimycotic solution (Hyclone) in the presence of 100 ng/ml IL-4 (PeproTech EC) 
and 80 ng/ml GM-CSF (Gentaur Molecular Products) added on day 0. Monocytes were 
cultured for four days in 12-well tissue culture plates at a density of 1.5 x 106 cells/ml in 
conditioned MSCl medium or in RPMI-1640 medium or were cultured for 4 days in T75 culture 
flasks at a density of 1.5×106 cells/ml in RPMI-1640 medium (Sigma-Aldrich). 
To determine the role of nuclear receptors, moDCs were differentiated in the presence 
or absence of 1 nM RARα activator, ATRA followed by a 75-min incubation period with or 
without 1 µM BMS-195614 (BMS614) specific RARα antagonist (Sigma-Aldrich) for 75 min at 
37°C atmosphere containing 5% CO2 prior to exchange the cell culture medium with or without 
MSCl-derived conditioned medium (MSCl-CM).  
 
Generation of MSCl cells  
Mesenchymal stromal cell-like cells derived from the human embryonic stem cell line HUES9 
was kindly provided by Douglas Melton, HHMI (Howard Hughes Medical Institute). MSCl cells 
were used according to the ethical permission 6681/2012/EHR. The cells were cultured on 
mitotically inactivated mouse embryonic fibroblast (MEF) to form embryonic bodies (EB) 
followed by trypsinization to obtain single cell cultures, which were further cultured on gelatin 
covered 10 cm plates in DMEM (Gibco) containing 10% FBS. Cells of the confluent cultures 
exhibited fibroblast like morphology and were further characterized in a collaborative study 
with the laboratory of Balázs Sarkadi, Membrane Research Group of the Hungarian Academy 
of Sciences, Semmelweis University and National Blood Service, Budapest, Hungary (Varga et 
al., 2011). MSCl cell passages in opto-mechanical-treated polystyrene flasks (TPP) provided 
coherent cell layers in the presence of L-glutamine, 10% FCS (Gibco) and 1% anti-
mycoticum/antibioticum solution (Hyclone) in low glucose DMEM (Gibco). The cultured MSCl 
cells were used after 10 passages. Confluent layer of MSCl cells was cultured in 12 ml RPMI 
(Sigma-Aldrich) supplemented with 10% FCS (Gibco) and 1% antibiotic/antimycotic solution 
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(Hyclone) for 48 hours to get the MSCl-CM. Synthesis of ATRA by MSCl cells was inhibited 
specifically by 1 µM N,N-diethylaminobenzaldehyde (DEAB) (Sigma-Aldrich) in the MSCl 
cultures for 24 h. After this incubation time MSCl cells were washed and fresh RPMI was added 
to the cells for 48 h. 
 
Co-cultures of moDC and MSCl cells  
MSCl cells were collected by using 0.05 –0.02% Trypsin/EDTA solution in Dulbecco’s PBS 
(DPBS), washed and cultured at a cell density of 3.6x106 cells in opto-mechanical treated T75 
flask for optimal cell growth (TPP). To achieve confluent cell layers the MSCl cells were 
cultured in 12 ml RPMI (Sigma-Aldrich) supplemented with 10% FCS (Gibco) containing 1% 
antimycotic/antibiotic solution (Hyclone) for minimum 12 hours. 1.8x107 freshly isolated 
monocytes were placed directly on the top of the adherent MSCl cells and the co-cultured 
moDCs were differentiated for four days in the presence of 80 ng/ml GM-CSF (Gentaur 
Molecular Products) and 100 ng/ml IL-4 (PeproTech). After the differentiation process moDCs 
were separated from MSCl cells by positive selection using immunomagnetic cell separation 




Phenotyping of resting, conditioned moDCs in the presence of MSCl-CM or with MSCl cells 
was performed by flow cytometry using anti-human CD14-fluorescein isothiocyanate (FITC), 
CD209/DC-SIGN-phycoerythrin (PE), CD1a-FITC, CD80-FITC, CD86-PE, PD-L1-PE, CD163-PE 
(BioLegend), CTLA-4-PE, CD1b-FITC, CD1c-allophycocyanin (APC) (Sony Biotechnology Inc.), 
HLA-DR-FITC (BD Biosciences). Cell viability was assessed by 7-aminoactinomycin-D (7-AAD; 
10 µg/ml; Sigma–Aldrich) staining for 15 minutes immediately before flow cytometric analysis. 
Fluorescence intensities were measured by FACS Calibur cytometer (BD Biosciences) and data 
were analyzed by the FlowJo software (Tree Star). 
 
Measurement of the cytokine concentrations  
Culture supernatants from moDCs, MSCl-CM exposed moDCs (CM-moDCs) or from co-cultures 
containing moDCs and MSCl cells were harvested 4 days after monocyte separation and the 
relative levels of selected human cytokines and chemokines were determined by Human XL 
Cytokine Array Kit following the manufacturer’s instructions (R&D Systems). Culture 
supernatants from moDCs, CM-moDCs or from co-cultures containing moDCs and MSCl cells 
were harvested 4 days after monocyte separation, and the concentration of IL-6, IL-10 and 
TGFβ cytokines was measured and validated by using OptEIA kits (BD Biosciences) following 
the manufacturer’s instructions.  
 
Treatment of moDCs to measure T-lymphocyte polarization  
Control, ATRA- or BMS614-pretreated moDCs and CM-moDCs were counted, washed and co-
cultured with allogenic peripheral blood lymphocytes (PBL) for three, five or nine days in 
RPMI-1640 medium (Sigma-Aldrich) at a moDC : T-cell ratio of 1 : 10 at 37°C. Parallel cultures 
of control moDCs and CM-moDCs were incubated with anti-CTLA-4 neutralizing antibody or 
with its isotype control IgG1 antibody (LifeSpan BioSciences) on ice for 1.5 h and then the cells 
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were washed and co-cultured with T cells for three, five or nine days in RPMI-1640 medium 
(Sigma) at a moDC : T-cell ratio of 1 : 10 at 37°C. The T cells were analyzed for IFNγ, IL-4, IL-17 
and IL-10 secretion by the avidin-horseradish peroxidase-based enzyme-linked ImmunoSpot 
(ELISPOT) system (NatuTec GmbH). Cultures including T cells or moDCs alone served as 
negative controls. To detect IFNγ, IL-4, IL-17 or IL-10 secretion the plates were coated with 0.5 
µg/ml mouse anti-hCD3 antibody (BD Biosciences). The plates were analyzed by using the 
ImmunoScan plate reader (Cell Technology Limited).  
To determine which T-lymphocyte populations are responsible for the cytokine 
production, after three, five or nine days the T cells were stimulated with 1µg/ml ionomycin 
and 20 ng/ml phorbol-myristic acetate (PMA) for 4 hours and the vesicular transport was 
inhibited by BD GolgiStop™ protein transport inhibitor (BD Biosciences) four hours before the 
cell staining. The cells were labelled with anti-human CD4-Peridinin Chlorophyll Protein 
Complex (PerCP) conjugated antibodies (BioLegend). Following this, they were fixed and 
permeabilized by using BD Cytofix/Cytoperm™ Plus Fixation/Permeabilization Kit (BD 
Biosciences) and labelled with anti-human IFNγ-APC (BD Biosciences), anti-human IL-4-PE 
(R&D Systems), anti-human IL-10-Alexa Fluor 488 and anti-human IL-17-PE antibodies 
(BioLegend). Fluorescence intensities were measured by FACS Calibur cytometer (BD 
Biosciences) and data were analyzed by the FlowJo software (Tree Star). 
 
Naïve CD4+ T-cell isolation 
Naive T-cells were separated from human blood mononuclear cells using the naive CD4+ T-
cell isolation kit based on negative selection according to the manufacturer’s instruction 
(Miltenyi Biotec). Using the CD4+ T Cell Isolation Kit, human CD4+ T helper cells are isolated 
by negative selection. Non-target cells are labeled with a cocktail of biotin-conjugated 
monoclonal antibodies and the CD4+ T Cell MicroBead Cocktail. The magnetically labeled non-
target T cells are depleted by retaining them on a MACS® Column in the magnetic field of a 
MACS Separator, while the unlabeled T helper cells pass through the column. 
 
RNA isolation, cDNA synthesis and real time quantitative PCR (RT-qPCR) 
Briefly, total RNA was isolated by TriReagent (Molecular Research Center). Total RNA was 
reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Gene-specific TaqMan pre-made assays (Applied Biosystems) were used to perform qPCR in a 
final volume of 12.5 μl in duplicates using DreamTaq DNA polymerase and ABI StepOnePlus 
real-time PCR instrument. Amplification of h36B4 was used as normalizing controls using 
specific primers and probe (Integrated DNA Technologies). Cycle threshold values were 
determined using the StepOne Software, version 2.1 (Applied Biosystems). The sequences of 
the primers and probes are available upon request. 
 
Statistical analysis 
Comparisons between two groups were performed using unpaired two-tailed Student’s t-test 
for normally distributed variables with equal variance and Mann–Whitney rank sum test for 
data that did not pass normality or equal variance test. Normality was assessed both visually 
(Q-Q plots) and through Shapiro-Wilk test. One-way ANOVA followed by Bonferroni’s post hoc 
test was used for comparisons for more than 2 groups. The results were expressed as mean ± 
10 
 
standard deviation. Analyses were performed by using Excel (Microsoft Corporation) and 
GraphPad Prism Version 6.0 (GraphPad Software Inc.) software. Differences were considered 
to be statistically significant at P < 0.05. Significance was indicated as *P < 0.05; **P < 0.01; 
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